Plasma levels of phosphorylated‐tau (P‐tau) are able to identify core Alzheimer’s Disease (AD) pathologies, but its value in cognitively unimpaired individuals needs further study. We aimed to investigate the value of plasma P‐tau at threonine...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O119463194
2021년
-
1552-5260
1552-5279
SCOPUS;SCIE
학술저널
n/a-n/a [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
Plasma levels of phosphorylated‐tau (P‐tau) are able to identify core Alzheimer’s Disease (AD) pathologies, but its value in cognitively unimpaired individuals needs further study. We aimed to investigate the value of plasma P‐tau at threonine...
Plasma levels of phosphorylated‐tau (P‐tau) are able to identify core Alzheimer’s Disease (AD) pathologies, but its value in cognitively unimpaired individuals needs further study. We aimed to investigate the value of plasma P‐tau at threonine‐181 (P‐tau181) for predicting amyloid pathology in cognitively unimpaired individuals followed over 10 years.
From the EMIF‐AD PreclinAD study we selected 74 individuals, aged 60 years and older (Table 1) with normal cognition, that had plasma samples available that were collected at time of amyloid status assessment, as well as 10 years earlier (median (IQR) = ‐9.7 (2)). Amyloid status was defined using visual read of dynamic [18F]flutemetamol‐PET images or CSF amyloid‐β1‐42/1‐40<0.065 (Euroimmun). Simoa assays were applied to measure plasma P‐tau181 levels (Eli Lilly). ROC curve analysis was used to determine the value of plasma P‐tau181 in predicting amyloid status. Further, linear mixed models, adjusted for age and sex, were applied to assess longitudinal change in plasma P‐tau181, using time and the interaction between time and amyloid status as a predictor.
Amyloid‐positive individuals had higher plasma P‐tau181 levels compared to amyloid‐negative individuals, both at time of amyloid status assessment and 10 years earlier. Plasma P‐tau181 obtained 10 years prior to amyloid status assessment was able to discriminate amyloid status with similar high Area Under Curve, sensitivity and specificity as plasma P‐tau181 obtained at time of amyloid status assessment (Figure 1). Longitudinally, we observed a general increase in plasma P‐tau181 levels over time (β=0.10, p<.001). Interestingly, amyloid‐positive individuals showed a steeper increase in plasma P‐tau181 levels over 10 years compared to amyloid‐negative individuals (time*amyloid‐β‐interaction: β=0.16, p=.005 (Figure 2)).
Our data suggest that plasma P‐tau181 can be used to predict AD pathology in cognitively unimpaired individuals. The high discriminative value observed, even using plasma P‐tau181 collected 10 years prior to amyloid status assessment, indicates the potential of this marker as an early amyloid pathology pre‐screening tool in the normal aging population. The observed amyloid dependent longitudinal increases in plasma P‐tau181 levels indicates this marker to be eligible for disease monitoring.